MAPT and tauopathy: VLP vaccines targeting tau pathology show strong potential for a multi-epitope immunotherapy approach, by combining VLPs targeting multiple pTau epitopes, for addressing tau pathology in AD and primary tauopathies lending a sense of optimism that a future without these diseases is possible.